The trimeric artesunate derivative TF27 exerts strong anti-cytomegaloviral efficacy: Focus on prophylactic efficacy and oral treatment of immunocompetent mice-Reference-Cited by-同舟云学术

The trimeric artesunate derivative TF27 exerts strong anti-cytomegaloviral efficacy: Focus on prophylactic efficacy and oral treatment of immunocompetent mice

Published:2020-06 Issue: Volume:178 Page:104788
ISSN:0166-3542
Container-title:Antiviral Research
language:en
Short-container-title:Antiviral Research

Author:

Wild Markus,Bertzbach Luca D.,Tannig Pierre,Wangen Christina,Müller Regina,Herrmann Lars,Fröhlich Tony,Tsogoeva Svetlana B.,Kaufer Benedikt B.,Marschall Manfred,Hahn Friedrich

Funder

Deutsche Forschungsgemeinschaft

Research Training Group

Wilhelm Sander-Stiftung

Publisher

Elsevier BV

Subject

Virology,Pharmacology

Reference36 articles.

1. Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods;Aickin;Am. J. Publ. Health,1996

2. A reporter system for Epstein-Barr virus (EBV) lytic replication: anti-EBV activity of the broad anti-herpesviral drug artesunate;Auerochs;J. Virol. Methods,2011

3. Artesunate derivative TF27 inhibits replication and pathogenesis of an oncogenic avian alphaherpesvirus;Bertzbach;Antivir. Res.,2019